Urologie pro praxi 4/2018
Treatment of metastatic clear-cell renal cell carcinoma – cabozantinib – experience and inclusion in treatment algorithm
Renal cell carcinoma, even in the metastatic setting, can be treatable, thus extending patient survival significantly. Cabozantinib administered after failure of treatment with tyrosine kinase inhibitors substantially prolonged the overall survival, delayed disease progression, and improved the rate of objective responses in patients with advanced clear-cell renal cell carcinoma who had received antiangiogenic therapy. Patients treated with it can maintain a good quality of life with an acceptable safety profile.
Keywords: metastatic clear-cell renal cell carcinoma, cabozantinib.
